We are developing a nerve imaging agent to guide surgeons during cancer resections. In 2024-2025 we plan on optioning or selling this “for profit” asset, and relocating to British Columbia to develop our “social impact” assets to treat (i) optic neuritis, that may presage multiple sclerosis; (ii) pain with non-opiate medication; and (iii) Optic Pathway Glioma, a children’s cancer of the optic nerve that affects patients with neurofibromatosis.